<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="101636">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01781390</url>
  </required_header>
  <id_info>
    <org_study_id>ANG.AMI-IC001</org_study_id>
    <nct_id>NCT01781390</nct_id>
  </id_info>
  <brief_title>Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in MyoCardial Infarction</brief_title>
  <acronym>AMICI</acronym>
  <official_title>A Prospective, Double Blind, Randomized, Placebo-controlled Clinical Trial of Intracoronary Infusion of Immunoselected, Bone Marrow-derived Stro3 Mesenchymal Precursor Cells (MPC) in the Treatment of Patients With ST-elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mesoblast, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mesoblast, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double blind, randomized, placebo controlled study that will enroll 225 subjects
      with de novo anterior myocardial infarction due to a lesion of the left anterior descending
      coronary artery undergoing PCI. Eligible subjects will be enrolled and undergo
      revascularization of the culprit LAD followed by an intracoronary (IC) delivery of the
      assigned treatment, infused into the stented culprit artery. The study will determine the
      safety and feasibility of the IC infusion of investigational MPCs in this patient
      population.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of the total major adverse cardiac and cerebrovascular events (MACCE)</measure>
    <time_frame>24 months</time_frame>
    <description>Occurrence of MACCE events including cardiac death, myocardial infarction, target vessel revascularization, stroke, new or worsening congestive heart failure during index hospitalization and cardiac hospitalizations due to congestive heart failure.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>12.5M Mesenchymal Precursor Cells (MPC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12.5M Mesenchymal Precursor Cell (MPC) administered via IC infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25M Mesenchymal Precursor Cells (MPC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25M Mesenchymal Precursor Cell (MPC) administered via IC infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo via IC infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>12.5 M Mesenchymal Precursor Cells (MPC)</intervention_name>
    <description>MPCs</description>
    <arm_group_label>12.5M Mesenchymal Precursor Cells (MPC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>25M Mesenchymal Precursor Cells (MPC)</intervention_name>
    <description>MPC</description>
    <arm_group_label>25M Mesenchymal Precursor Cells (MPC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Clinical symptoms consistent with AMI (pain, etc.) for a maximum of 12 hours from
             onset of symptoms to percutaneous coronary intervention (PCI)

          -  De Novo anterior Acute Myocardial Infarct (AMI)

          -  Successful revascularization of the culprit lesion

        Key Exclusion Criteria:

          -  Prior AMI, known cardiomyopathy, or hospital admission for heart failure (HF)

          -  Significant valvular disease

          -  Need for other interventional or surgical procedure to treat heart disease (planned
             or scheduled)

          -  Cardiogenic shock or hemodynamic instability within 24 hours of randomization

          -  Prior PCI to LAD

          -  Pacemaker, ICD (Implantable Cardioverter Defibrillator), or any other
             contra-indication for cardiac MRI

          -  Prior or current participation in any stem cell study or any other investigational
             trial in the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee Golden, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mesoblast, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Duckers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>New Zealand</country>
  </removed_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 13, 2016</lastchanged_date>
  <firstreceived_date>January 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>STEMI</keyword>
  <keyword>Heart Attack</keyword>
  <keyword>AMI</keyword>
  <keyword>Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
